South San Francisco, CA — December 12th, 2023 —
Ashley Magargee has been appointed to the role of Chief Executive Officer of Genentech, a member of the Roche Group, effective January 1, 2024. In addition to her role as Head of US Commercial Portfolio, Magargee has been serving as ad interim CEO since the departure of Alexander Hardy on November 1, 2023. She will report to Teresa Graham, CEO of Roche Pharma, and become a member of the Pharma Leadership Team.
Magargee joined Genentech in 2004 and has held senior management positions at Roche and Genentech in lifecycle management, digital customer experience, market access and was also the General Manager in Singapore. Most recently, she served as Head of Commercial Portfolio, Genentech.
"Ashley is a Roche and Genentech veteran, with a 20-year career that spans the breadth of our business. I personally value her deep commitment to our people and strong regard for the stakeholders with which we partner across the healthcare system," said Teresa Graham, CEO of Roche Pharma.
Founded more than 40 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious and life-threatening medical conditions. The company, a member of the Roche Group, has headquarters in South San Francisco, California. For additional information about the company, please visit http://www.gene.com.